New DNA-Based Immunotherapy Passes First Safety Test in Adults with Type 1 Diabetes

A Phase 1 trial of NNC0361-0041, an experimental plasmid-DNA immunotherapy developed by Novo Nordisk and TrialNet, has completed enrollment and demonstrated early safety findings in adults. The results represent an important first step toward understanding how this immune-targeting approach might work in type 1 diabet…

Video report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

NNC0361-0041 is a plasmid-DNA immunotherapy—a new class of treatment that uses genetic material to train the immune system—tested for the first time in type 1 diabetes patients
The TOPPLE Phase 1 trial enrolled 47 adults and focused on safety and tolerability, the critical first milestone in drug development
Early safety results from this trial have been completed, allowing researchers to move toward next-stage studies
This approach is different from current type 1 diabetes treatments; it aims to address the underlying immune dysfunction rather than manage blood sugar alone

What This Trial Tested

The TOPPLE trial evaluated NNC0361-0041, a plasmid-DNA immunotherapy co-developed by Novo Nordisk and TrialNet, in 47 adults with type 1 diabetes. Phase 1 trials are designed to answer basic questions: Is the treatment safe? What side effects occur? What dose is tolerable? This early-stage trial was not designed to measure whether the therapy slows or halts type 1 diabetes progression—that would come later if safety is established.

How Plasmid-DNA Immunotherapy Works

Unlike insulin or current medications, plasmid-DNA immunotherapy attempts to retrain the immune system by introducing genetic instructions that direct immune cells toward a more tolerant state. In type 1 diabetes, the immune system mistakenly attacks insulin-producing beta cells. This class of treatment aims to shift that immune response, rather than simply replacing the insulin the body can no longer make.

What's Next

Safety data from TOPPLE provide the foundation for next-stage research. If the therapy continues to show an acceptable safety profile, researchers will design larger, longer trials to explore whether it can slow or delay the loss of beta-cell function in people with type 1 diabetes. This is a standard progression in drug development and does not guarantee the treatment will prove effective or eventually reach patients.

Why This Matters for the Type 1 Community

Type 1 diabetes research is pursuing multiple avenues to address the underlying immune dysfunction, not just manage blood sugar levels. Plasmid-DNA immunotherapy represents one experimental approach. While early-stage results are encouraging, it remains investigational. The type 1 diabetes community benefits when diverse approaches are tested rigorously—but it is important to distinguish between promising early data and proven treatments.

Evidence label

Origin: T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.